Clinical trials: BRCA1 Mutation Carrier
Breast Cancer
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
Women with a BRCA1 mutation face a lifetime risk of breast cancer of approximately 70% and a lifetime risk of ovarian cancer of approximately 40%.
- Trial name
- NCT01022333
- Testing
- Diindolylmethane (DIM)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Hereditary Breast and Ovarian Cancer Syndrome
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
Breast cancer (BC) is a major health problem and the most prevalent cancer among women.In a substantial proportion of familial cases, germ-line mutations in either BRCA1/2 can be detected.
- Trial name
- NCT03162276
- Testing
- Inquiry Based Stress Reduction (IBSR) program, Control
- Where
- 2 sites in Israel
- Volunteers
- 118 people
- Sponsor
- Sheba Medical Center
Fallopian Tube, Primary Peritoneal Cancer
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 1, dose escalation trial evaluating the tolerability, pharmacokinetics, and pharmacodynamics of ABT-767 in subjects with advanced Breast Cancer 1 or 2 gene (BRCA1 or BRCA2)-mutated solid tumors and high grade…
- Conditions
- Fallopian Tube, Primary Peritoneal Cancer, Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
- Trial name
- NCT01339650
- Testing
- ABT-767
- Where
- 3 sites in Netherlands
- Volunteers
- 93 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hereditary Breast and Ovarian Cancer
Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
BRCA1/2 mutation carriers have a considerably increased risk to develop breast and ovarian cancer during their lifetime. There is evidence from the literature that for sporadic breast cancer disease risk and the course of disease…
- Trial name
- LIBRE (NCT02087592)
- Testing
- Structured exercise training plus mediterranean diet
- Where
- 3 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Technical University of Munich
brca1 Mutation Carrier, brca2 Mutation Carrier
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00098800
- Testing
- fenretinide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Hereditary Breast and Ovarian Cancer Syndrome
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
Breast cancer (BC) is a major health problem and the most prevalent cancer among women.In a substantial proportion of familial cases, germ-line mutations in either BRCA1/2 can be detected.
- Trial name
- NCT01367639
- Testing
- Inquiry Based Stress Reduction (IBSR) program
- Where
- Israel
- Volunteers
- 67 people
- Sponsor
- Sheba Medical Center
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy).
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02314156
- Testing
- Telapristone Acetate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Northwestern University
brca1 Mutation Carrier, brca2 Mutation Carrier
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00986206
- Testing
- Biomarker LPA and HE4
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Breast Neoplasms
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another…
- Trial name
- NCT00580112
- Testing
- Dexamethasone, Trabectedin
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
BRCA1 Mutation, BRCA2 Mutation
Radical Fimbriectomy for Young BRCA Mutation Carriers
Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible…
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Hereditary Breast and Ovarian Cancer
- Trial name
- FIMBRIECTOMIE (NCT01608074)
- Testing
- Radical fimbriectomy, Histopathology SEE-FIM
- Where
- 14 sites in France
- Volunteers
- 123 people
- Sponsor
- Centre Oscar Lambret
BRCA Mutations
The Use of Digital Genetic Counselor (DGC) for BRCA1/2 Mutation Carrier Testing
The DGC provides an end-to-end solution to the Oncogenetics screening process from participant registration to receipt of the genetic test results and their interpretation.
- Trial name
- NCT04038905
- Volunteers
- 300 people
- Sponsor
- Igentify Ltd
Cancer Genetics
Adaptation to Living With a BRCA1/2 Mutation
Background: Women who have a BRCA1/2 gene mutation have a very high risk of developing breast or ovarian cancer. They are also at increased risk of other developing other cancers.
- Trial name
- NCT01866865
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
brca1 Mutation Carrier, brca2 Mutation Carrier
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00321633
- Testing
- carboplatin, docetaxel
- Where
- 25 sites in Australia, Israel and 4 more
- Volunteers
- 148 people
- Sponsor
- University College London Hospitals
BRCA1 Mutation, BRCA2 Mutation
FaCT Trial (Facilitated Cascade Testing Trial)
The purpose of this study is to assess an intervention that incorporates engagement strategies with a medical team navigator, an educational video and accessible genetic testing services to maximize the genetic testing and…
- Trial name
- NCT04613440
- Testing
- Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing
- Where
- 3 sites in United States
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
brca1 Mutation Carrier, brca2 Mutation Carrier
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT01097278
- Testing
- cholecalciferol
- Where
- 360 sites in United States
- Volunteers
- 208 people
- Sponsor
- SWOG Cancer Research Network
BRCA1 Mutation, High-grade Serous Ovarian Cancer
Breast Cancer BRCA1 Carriers: a Pilot Study
The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates…
- Conditions
- BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05062174
- Testing
- Mifepristone 200 MG, Prophylactic mastectomy
- Where
- 2 sites in United States
- Sponsor
- Indiana University